Novel agents and approaches for advanced renal cell carcinoma

Journal of Urology

Volumn 188, Issue 3, 2012, Pages 707-715

  Figlin, Robert ^a   Sternberg, Cora ^b   Wood, Christopher G ^c  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

antineoplastic agents; carcinoma; clinical trials as topic; immunomodulation; kidney; renal cell

Indexed keywords

8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; AFLIBERCEPT; AGS 003; ALPHA INTERFERON; AXITINIB; BEVACIZUMAB; CEDIRANIB; CYCLOPHOSPHAMIDE; DOVITINIB; ENDOTHELIAL CELL GROWTH FACTOR; EVEROLIMUS; GEFITINIB; IMA901; IMMUNOMODULATING AGENT; LENVATINIB; NINTEDANIB; NIVOLUMAB; PAZOPANIB; PROTEIN KINASE B INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; RAMUCIRUMAB; REGORAFENIB; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TIVOZANIB; TREBANANIB; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR;

ADVANCED CANCER; ALOPECIA; ANGIOGENESIS; ANOREXIA; ANTINEOPLASTIC ACTIVITY; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CONSTIPATION; DIARRHEA; DISEASE SEVERITY; DRUG APPROVAL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SCREENING; DYSPHONIA; DYSPNEA; FATIGUE; HEADACHE; HEMATURIA; HUMAN; HYPERTENSION; INJECTION SITE REACTION; KIDNEY CARCINOMA; LYMPHOCYTOPENIA; MOLECULARLY TARGETED THERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEINURIA; QUALITY OF LIFE; RASH; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SKIN MANIFESTATION; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION; TUMOR GROWTH; TUMOR VOLUME;

CARCINOMA, RENAL CELL; CLINICAL TRIALS AS TOPIC; HUMANS; KIDNEY NEOPLASMS; NEOPLASM STAGING;

EID: 84864936038     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2012.04.108     Document Type: Review

References (50)

1. NCCN Clinical Practice Guidelines in Oncology™ for Kidney Cancer, v. 2.2011 National Comprehensive Cancer Network http://www.nccn.org/ professionals/physician-gls/f-guidelines.asp#kidney Accessed April 26, 2011
2. K. Gupta, J.D. Miller, J.Z. Li Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review Cancer Treat Rev 34 2008 193
3. G.R. Hudes, M.A. Carducci, T.K. Choueiri NCCN Task Force report: optimizing treatment of advanced renal cell carcinoma with molecular targeted therapy J Natl Compr Canc Netw 9 suppl 2011 S1
4. B. Ljungberg, N.C. Cowan, D.C. Hanbury EAU guidelines on renal cell carcinoma: the 2010 update Eur Urol 58 2010 398
5. D.D. Hu-Lowe, H.Y. Zou, M.L. Grazzini Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3 Clin Cancer Res 14 2008 7272
6. B.I. Rini, G. Wilding, G. Hudes Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma J Clin Oncol 27 2009 4462
7. O. Rixe, R.M. Bukowski, M.D. Michaelson Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study Lancet Oncol 8 2007 975
8. R.J. Motzer, T. de La Motte Rouge, A.L. Harzstark Axitinib second-line therapy for metastatic renal cell carcinoma (mRCC): five-year (yr) overall survival (OS) data from a phase II trial J Clin Oncol 29 suppl 2011 abstract 4547
9. Y. Tomita, H. Uemura, H. Fujimoto Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a Japanese phase II study in patients with cytokine-refractory metastatic renal cell cancer (mRCC) Ann Oncol 21 suppl 2010 282 abstract 902P
10. B.I. Rini, B. Escudier, P. Tomczak Axitinib versus sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC): results of phase III AXIS trial J Clin Oncol 29 suppl 2011 abstract 4503
11. D. Cella, B. Escudier, B.I. Rini Patient-reported outcomes (PROs) in a phase III AXIS trial of axitinib versus sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC) J Clin Oncol 29 suppl 2011 abstract 4504
12. E. Jonasch, A. Bair, Y. Chen, B.I. Rini Axitinib with or without dose titration as first-line therapy for metastatic renal cell carcinoma (mRCC) J Clin Oncol 28 suppl 2010 abstract TPS235
13. A. De Luca, N. Normanno Tivozanib, a pan-VEGFR tyrosine kinase inhibitor for the potential treatment of solid tumors IDrugs 13 2010 636
14. D. Nosov, P. Bhargava, W.B. Esteves Final analysis of the phase II randomized discontinuation trial (RDT) of tivozanib (AV-951) versus placebo in patients with renal cell carcinoma (RCC) J Clin Oncol 29 suppl 2011 abstract 4550
15. R.J. Motzer, P. Bhargava, B. Esteves A phase III, randomized, controlled study to compare tivozanib with sorafenib in patients (pts) with advanced renal cell carcinoma (RCC) J Clin Oncol 29 suppl 2011 abstract 310
16. D. Sarker, R. Molife, T.R. Evans A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors Clin Cancer Res 14 2008 2075
17. E. Angevin, V. Grunwald, A. Ravaud A phase II study of dovitinib (TKI258), an FGFR- and VEGFR-inhibitor, in patients with advanced or metastatic renal cell cancer (mRCC) J Clin Oncol 29 suppl 2011 abstract 4551
18. C. van Herpen, J. Drevs, H. van Cruijsen Evaluation of AZD2171, an oral, highly potent and selective VEGFR signaling inhibitor, in renal cell carcinoma (RCC): combined results from two phase I studies J Clin Oncol 25 suppl 2007 abstract 3560
19. S.S. Sridhar, M.J. Mackenzie, S.J. Hotte Activity of cediranib (AZD2171) in patients (pts) with previously untreated metastatic renal cell cancer (RCC) A phase II trial of the PMH Consortium J Clin Oncol 26 suppl 2008 abstract 5047
20. P. Mulders, R. Hawkins, P. Nathan Final results of a Phase II randomised study of cediranib (RECENTIN™) in patients with advanced renal cell carcinoma (RCC) Eur J Cancer 7 suppl 2009 21 abstract 49LBA
21. E. Jonasch, P. Lara, N.M. Tannir A randomized phase II study of MK-2206 in comparison with everolimus in refractory renal cell carcinoma. (NCI 8727) J Clin Oncol 29 suppl 2011 abstract TPS192
22. A. Biondo, T.A. Yap, L. Yan Phase I clinical trial of an allosteric AKT inhibitor, MK-2206, using a once weekly (QW) dose regimen in patients with advanced solid tumors J Clin Oncol 29 suppl 2011 abstract 3037
23. F. Hilberg, G.J. Roth, M. Krssak BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy Cancer Res 68 2008 4774
24. K. Mross, M. Stefanic, D. Gmehling Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors Clin Cancer Res 16 2010 311
25. K. Yamada, N. Yamamoto, Y. Yamada Phase I dose-escalation study and biomarker analysis of E7080 in patients with advanced solid tumors Clin Cancer Res 17 2011 2528
26. R.S. Herbst, D. Hong, L. Chap Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors J Clin Oncol 27 2009 3557
27. L.J. Appleman, M.S. Gordon, W. Samlowski Open-label phase 1b study of AMG 386, a selective angiopoietin1/2-neutralizing peptibody, in combination with sorafenib or sunitinib in advanced renal cell carcinoma (RCC): interim results Ann Oncol 21 suppl 2010 viii65 abstract 505P
28. B.I. Rini, C. Szczylik, N.M. Tannir AMG 386 in combination with sorafenib in patients (pts) with metastatic renal cell cancer (mRCC): a randomized, double-blind, placebo-controlled, phase II study J Clin Oncol 29 suppl 2011 abstract 309
29. H.M. Verheul, H. Hammers, K. van Erp Vascular endothelial growth factor trap blocks tumor growth, metastasis formation, and vascular leakage in an orthotopic murine renal cell cancer model Clin Cancer Res 13 2007 4201
30. J. Dupont, M.L. Rothenberg, D.R. Spriggs Safety and pharmacokinetics of intravenous VEGF Trap in a phase I clinical trial of patients with advanced solid tumors J Clin Oncol 23 suppl 2005 abstract 3029
31. T. Eisen, H. Joensuu, P. Nathan Phase II trial of the oral multikinase inhibitor BAY 73-4506 as 1st-line therapy in patients with metastatic or unresectable renal cell cancer (RCC) Eur J Cancer 7 suppl 2009 424 abstract 7105
32. J.L. Spratlin, R.B. Cohen, M. Eadens Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 J Clin Oncol 28 2010 780
33. Garcia JA, Hudes GR, Choueiri TK, et al. Phase II study of IMC-1121B in patients with metastatic renal cancer (mRCC) following VEGFR-2 tyrosine kinase inhibitor (TKI) therapy (IMCL CP12-0605/ NCT00515697). Presented at American Society of Clinical Oncology Genitourinary Cancers Symposium, San Francisco, California, March 5-7, 2010, abstract 326.
34. M. Staehler, A. Stenzl, P.Y. Dietrich A phase I study to evaluate safety, immunogenicity and anti-tumor activity of the multi-peptide vaccine IMA901 in renal cell carcinoma patients (RCC) J Clin Oncol 25 suppl 2007 abstract 5098
35. C. Reinhardt, R. Zdrojowy, C. Szczylik Results of a randomized phase II study investigating multipeptide vaccination with IMA901 in advanced renal cell carcinoma (RCC) J Clin Oncol 28 suppl 2010 abstract 4529
36. B.I. Rini, T. Eisen, A. Stenzl IMA901 Multipeptide Vaccine Randomized International Phase III Trial (IMPRINT): a randomized, controlled study investigating IMA901 multipeptide cancer vaccine in patients receiving sunitinib as first-line therapy for advanced/metastatic RCC J Clin Oncol 29 suppl 2011 abstract TPS183
37. J.R. Brahmer, C.G. Drake, I. Wollner Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates J Clin Oncol 28 2010 3167
38. R.H. Thompson, H. Dong, C.M. Lohse PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma Clin Cancer Res 13 2007 1757
39. D.F. McDermott, C.G. Drake, M. Sznol A phase I study to evaluate safety and antitumor activity of biweekly BMS-936558 (Anti-PD-1, MDX-1106/ONO-4538) in patients with RCC and other advanced refractory malignancies J Clin Oncol 29 suppl 2011 abstract 331
40. R.A. Figlin, C.A. Nicolette, A. Amin Monitoring T-cell responses in a phase II study of AGS-003, an autologous dendritic cell-based therapy in patients with newly diagnosed advanced stage renal cell carcinoma in combination with sunitinib J Clin Oncol 29 suppl 2011 abstract 2532
41. A. Amin, A. Dudek, T. Logan A phase II study testing the safety and activity of AGS-003 as an immunotherapeutic in subjects with newly diagnosed advanced stage renal cell carcinoma (RCC) in combination with sunitinib J Clin Oncol 28 suppl 2010 abstract 4588
42. J.J. Knox, A.C. Kay, E. Schiff First-line everolimus followed by second-line sunitinib versus the opposite treatment sequence in patients with metastatic renal cell carcinoma (mRCC) J Clin Oncol 28 suppl 2010 abstract TPS232
43. D.R. Feldman, M.S. Baum, M.S. Ginsberg Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma J Clin Oncol 27 2009 1432
44. D.M. Waterhouse, W.C. Penley, C.D. Webb Sorafenib and everolimus (RAD001) in the treatment of patients with advanced clear cell renal carcinoma (RCC): a Sarah Cannon Research Institute phase I/II trial J Clin Oncol 29 suppl 2011 abstract 4629
45. B.J. Escudier, S. Negrier, G. Gravis Can the combination of temsirolimus and bevacizumab improve the treatment of metastatic renal cell carcinoma (mRCC)? Results of the randomized TORAVA phase II trial J Clin Oncol 28 suppl 2010 abstract 4516
46. F.F. Kabbinavar, S. Srinivas, R.J. Hauke Results from a phase I trial of tivozanib (AV-951) combined with temsirolimus therapy in patients (pts) with renal cell carcinoma (RCC) J Clin Oncol 29 suppl 2011 abstract 4549
47. S.K. Pal, R.A. Figlin Renal cell carcinoma therapy in 2010: many options with little comparative data Clin Adv Hematol Oncol 8 2010 191
48. R.I. Fisher, S.A. Rosenberg, G. Fyfe Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma Cancer J Sci Am 6 suppl 2000 S55
49. D.F. McDermott, M.S. Ghebremichael, S. Signoretti The high-dose aldesleukin (HD IL-2) "SELECT" trial in patients with metastatic renal cell carcinoma (mRCC) J Clin Oncol 28 suppl 2010 abstract 4514
50. T.E. Hutson, J. Sarantopoulos, T. Logan Phase I/II study of BNC105P in combination with everolimus or following everolimus for progressive metastatic renal cell carcinoma following prior tyrosine kinase inhibitors J Clin Oncol 29 suppl 2011 abstract TPS194